BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 22728515)

  • 1. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
    Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
    J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake.
    Takara K; Hatakeyama H; Ohga N; Hida K; Harashima H
    Int J Pharm; 2010 Aug; 396(1-2):143-8. PubMed ID: 20457236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system.
    Kibria G; Hatakeyama H; Harashima H
    Int J Pharm; 2011 Jun; 412(1-2):106-14. PubMed ID: 21414394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
    Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C
    J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
    Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
    Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
    Yang Y; Yang Y; Xie X; Wang Z; Gong W; Zhang H; Li Y; Yu F; Li Z; Mei X
    Biomaterials; 2015 Apr; 48():84-96. PubMed ID: 25701034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
    J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
    Kibria G; Hatakeyama H; Sato Y; Harashima H
    Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery.
    Tang J; Fu H; Kuang Q; Zhang L; Zhang Q; Liu Y; Ran R; Gao H; Zhang Z; He Q
    J Drug Target; 2014 May; 22(4):313-26. PubMed ID: 24404866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth.
    Wang Z; Yu Y; Dai W; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2013 Jan; 34(3):756-64. PubMed ID: 23117217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
    Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
    Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
    Corti A; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.